生物制剂在慢性自发性荨麻疹治疗中的应用进展  

Advances in the applications of biologics in the treatment of chronic spontaneous urticaria

作　　者：黄雪梅[1] 欧珊珊 陈教全 邹荟 陈紫嫣 吴伟鸿 吴慧 李润祥[1] 朱慧兰[1] HUANG Xuemei;OU Shanshan;CHEN Jiaoquan;ZOU Hui;CHEN Ziyan;WU Weihong;WU Hui;LI Runxiang;ZHU Huilan(Guangzhou Institute of Dermatology,Guangzhou 510095,China;Guangzhou Medical University,Guangzhou 511436,China)

机构地区：[1]广州市皮肤病防治所,广东广州510095 [2]广州医科大学,广东广州511436

出　　处：《皮肤性病诊疗学杂志》2024年第2期136-141,共6页Journal of Diagnosis and Therapy on Dermato-venereology

基　　金：广州市科技计划项目(2022A03J00252,SL2024A03J00856)。

摘　　要：慢性自发性荨麻疹(CSU)是一种临床常见的免疫反应性皮肤病,其发病的关键效应细胞是肥大细胞。随着近年来对CSU发病机制的不断认识,不少新型生物制剂被应用于CSU患者的治疗。生物制剂可通过靶向作用于肥大细胞的活化过程的不同阶段,阻断肥大细胞的活化、脱颗粒,从而有效治疗CSU;根据作用靶点和作用机制,可分为抑制肥大细胞激活、抑制胞内信号转导、激活抑制性受体的药物。本文对生物制剂在CSU治疗中的应用展开综述。Chronic spontaneous urticaria(CSU)is a common immune skin disease in clinic.Mast cells are the key effector cells in the pathogenesis of CSU.With the continuous understanding of the pathogenesis of CSU in recent years,many new biologics have been used to treat CSU.Biologics can effectively treat CSU by targeting different stages of mast cell activation,blocking their activation and degranulation.According to the target and mechanisms of their action,biologics can be classified into inhibition of mast cell activation and intracellular signaling transduction,and activation of inhibitory receptor.This article will review the applications of biologics in the treatment of CSU.

关 键 词：慢性自发性荨麻疹 生物制剂 治疗 

分 类 号：R758.24[医药卫生—皮肤病学与性病学]